Full-service clinicalRank #6 of 12Prescribes

Vida Health

Item: Vida Health
Rating: 7.5
Author: MyGLP Reviews

Combined cardiometabolic and mental health care in one care team

Founded 2014 · San Francisco, CA · Private · Website

7.5Strong

Weighted score

Strong

Reviewed September 19, 2026

PMPM benchmark

$38–$78

Category planning band — not a vendor quote. Excludes drug spend.

Our verdict

A thoughtful pick when behavioral health is part of your thesis and you have no strong incumbent. Otherwise you are buying overlap — make them price the weight component standalone.

Scorecard

How it scored

Scored against the published rubric. Weights are fixed before review and identical for every vendor.

How scoring works

Clinical rigor7.6

Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.

Outcomes evidence7.3

Quality of published results: peer review, sample size, control group, and follow-up duration.

Cost control7.2

Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.

Data & reporting7.7

Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.

Integration7.8

PBM, carrier, HRIS, and point-solution interoperability without custom engineering.

Member experience7.9

Time to first appointment, app quality, care-team continuity, and support responsiveness.

Analysis

What we found

Vida's integration of behavioral health into metabolic care is a genuine differentiator rather than a marketing overlay, and it is well timed given growing attention to mood and disordered-eating effects during GLP-1 therapy. Requiring behavioral-health screening before initiation is a safeguard no other vendor in this set enforces. The honest limitation is that Vida is very good at two things rather than exceptional at either, and buyers with an incumbent mental health vendor will be paying twice for part of it.

Strengths

Only vendor here that treats behavioral health as core rather than a referral, which matters given documented mood effects
Mandatory behavioral-health screening before initiation is a real clinical safeguard competitors skip
Consolidating weight management and mental health into one vendor removes a contract and a care handoff

Limitations

Neither the weight nor the mental health side is best-in-class in isolation
Outcomes evidence is solid but not distinctive within the category
Combined model complicates ROI attribution — hard to tell which half is producing the result

Best for

Employers who already see behavioral health and metabolic health as one problem and want a single accountable vendor.

Watch out

If you already run a strong EAP or mental health vendor, you are buying overlap. Price the weight-management component alone.

The details

Commercial and clinical specifics

The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.

Pricing

Model: PMPM on enrolled members, with outcomes-based tiers available
PMPM range: $38–$78
Setup fee: Waived above 3,000 lives
Medications included: No
Performance guarantees: Clinical and engagement guarantees; commonly 20–30% of fees at risk

Contract

Minimum lives: 1,000
Term: 24 months
Termination notice: 90 days

Eligibility

BMI threshold: BMI ≥ 27
Prior authorization: Yes
Step therapy: Yes
Comorbidity required: No

Clinical model

Prescribes: Yes
Care team: Physicians, Nurse practitioners, Licensed therapists, Registered dietitians, Health coaches
Titration protocol: Protocolized with mandatory behavioral-health screening before initiation
Off-ramp: Integrated maintenance with continuing mental health support
Formulary: Semaglutide, Tirzepatide, Metformin, Bupropion/naltrexone

Outcomes evidence

Headline claim: Improvements in glycaemic control alongside reductions in depressive symptoms, in peer-reviewed retrospective analyses of its combined cardiometabolic and mental health programme
Evidence level: Peer-reviewed observationalPublished cohort data, no randomization.
Sample size: 1,128 participants in the glycaemic analysis
Follow-up: Retrospective, with follow-up varying by cohort

Sources

Improvements in glycaemic control and depressive symptoms among adults with type 2 diabetesRetrospective study, August 2022, 1,128 participants
Improvements in depression outcomes following a digital programme (JMIR Formative)Peer-reviewed mental health outcomes

Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.

Integrations

PBMs: CVS Caremark, Express Scripts, Optum Rx
Carriers: Aetna, Cigna, UnitedHealthcare
HRIS: Workday, ADP, UKG
Eligibility file: 834 or flat file, weekly cadence

Formulary

Vida Health by medication

How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.

Vida Health Reviews Semaglutide

GLP-1 receptor agonist

Escalation only

Reached after a documented lower-cost trial, and — uniquely in this set — only after a behavioral-health screen. Given documented mood and disordered-eating considerations during rapid weight loss, that screen is a real clinical safeguard competitors skip.

Read pairing

Vida Health Reviews Tirzepatide

Dual GIP/GLP-1 receptor agonist

Escalation only

Same escalation and screening pathway. The behavioral-health integration matters more at tirzepatide's efficacy level, where larger and faster reductions amplify both the mood and lean-mass considerations.

Read pairing